MG Clinical Trials in Wuhan, Hubei
4 recruitingWuhan, Hubei, China
Showing 1–4 of 4 trials
Recruiting
Early Phase 1
CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Tongji Hospital36 enrolled1 locationNCT07337785
Recruiting
Phase 1
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+4 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Not Applicable
Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
SclerodermaMyasthenia Gravis (MG)System Lupus Erythematosus(SLE)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07470151
Recruiting
Early Phase 1
GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)
Generalized Myasthenia Gravis (gMG)
Daishi Tian6 enrolled1 locationNCT07058298